JPH0729911B2 - External skin preparation - Google Patents
External skin preparationInfo
- Publication number
- JPH0729911B2 JPH0729911B2 JP61111328A JP11132886A JPH0729911B2 JP H0729911 B2 JPH0729911 B2 JP H0729911B2 JP 61111328 A JP61111328 A JP 61111328A JP 11132886 A JP11132886 A JP 11132886A JP H0729911 B2 JPH0729911 B2 JP H0729911B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- weight
- external preparation
- glycyrrhizic acid
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 18
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 15
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 15
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 14
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 14
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 14
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical class CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- -1 P-methoxycinnamic acid ester compound Chemical class 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical class [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- NXNNGQHUTNFYKK-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-ethylhexanoate;3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(C=CC(O)=O)C=C1.CCCCC(CC)C(=O)OCC(O)CO NXNNGQHUTNFYKK-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- PNXGFGZBINFRSQ-UHFFFAOYSA-N OC(=O)C=CC1=CC=CC=C1.CCCCC(CC)C(=O)OCC(O)CO Chemical compound OC(=O)C=CC1=CC=CC=C1.CCCCC(CC)C(=O)OCC(O)CO PNXGFGZBINFRSQ-UHFFFAOYSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明は、抗炎症効果に優れた皮膚外用剤、さらに詳し
くは、グリチルリチン酸およびはその誘導体の１種また
は２種以上と、一般式に示されるＰ−メトキシケイ皮酸
エステル化合物とを配合することを特徴とする皮膚外用
剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a skin external preparation having an excellent anti-inflammatory effect, more specifically, one or more glycyrrhizic acid and its derivatives, and a compound represented by the general formula: It relates to a skin external preparation characterized by being blended with the P-methoxycinnamic acid ester compound shown.
［従来の技術］ 従来、日焼け、湿疹などの炎症には、カラミンなどの収
れん剤、ビタミンＣなどのビタミン剤、スルファジアジ
ンなどの抗ヒスタミン剤、バシトラシンなどの抗生物
質、フルオシノロンアセトナイドなどの副腎皮質ホルモ
ン剤、アズレンなどが用いられているがこれらの薬剤
は、ほかの配合成分との関係から、効果を発揮できなか
ったり、局所適用における安全性、有効性の点で、必ず
しも満足しえない。[Prior art] Conventionally, for inflammation such as sunburn and eczema, astringents such as calamine, vitamins such as vitamin C, antihistamines such as sulfadiazine, antibiotics such as bacitracin, and adrenal cortex such as fluocinolone acetonide. Hormonal agents, azulene, etc. are used, but these agents are not always satisfactory in terms of their effects with respect to other ingredients and in terms of safety and effectiveness in topical application.
一方、グリチルリチン酸および／または、その誘導体
が、抗炎症効果があることは、知られるところである。
しかし、その効果は、緩和であり抗炎症作用を期待する
皮膚外用剤に用いる場合、高配合しなければ効果が得ら
れなかった。On the other hand, it is known that glycyrrhizic acid and / or its derivative has an anti-inflammatory effect.
However, when used in an external preparation for skin, which is mild and expected to have an anti-inflammatory effect, the effect could not be obtained unless the content was high.
［発明が解決しようとする問題点］ 本発明者らは、グリチルリチン酸および／または、その
誘導体の抗炎症作用をさらに高める方法はないものかと
鋭意研究の結果、グリチルリチン酸およびその誘導体の
１種または２種以上と、ともにＰ−メトキシケイ皮酸エ
ステルとを配合することにより、この目的が達成できる
ことを見出して、本発明を完成した。[Problems to be Solved by the Invention] The present inventors have earnestly studied whether or not there is a method for further enhancing the anti-inflammatory action of glycyrrhizic acid and / or its derivative, and as a result, one of glycyrrhizic acid and its derivative or The present invention has been completed by finding that this object can be achieved by blending two or more kinds and P-methoxycinnamic acid ester together.
［問題点を解決するための手段］ すなわち、本発明は、グリチルリチン酸およびその誘導
体の１種または２種以上0.001〜５重量％と、一般式
（１）〜（５）で表されるＰ−メトキシケイ皮酸エステ
ルの一種または二種以上0.1〜15重量％とを含有し、両
者の合計が1.1％以上であることを特徴とする皮膚外用
剤。[Means for Solving Problems] That is, according to the present invention, one or more of glycyrrhizinic acid and its derivatives, 0.001 to 5% by weight, and P- represented by the general formulas (1) to (5) are used. An external preparation for skin, comprising 0.1 to 15% by weight of one or more kinds of methoxycinnamic acid ester, and the total amount of both is 1.1% or more.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be described in detail.
本発明で用いられるグリチルリチン酸は、次に示す構造
式で表される化合物である。Glycyrrhizic acid used in the present invention is a compound represented by the following structural formula.
また、グリチルリチン酸の誘導体としては、グリチルリ
チン酸ジカリウム、グリチルリチン酸モノアンモニウ
ム、グリチルリチン酸ステアレート、などが有名であ
る。 In addition, as the derivative of glycyrrhizinic acid, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, stearate glycyrrhizinate, and the like are famous.
配合量は、皮膚外用剤全量中の0.001〜５重量％、好ま
しくは、0.01〜１重量％、さらに好ましくは、0.05〜0.
1重量％である。0.001重量％未満では、グリチルリチン
酸および／または、その誘導体の効果は、期待できず、
５重量％を越えるとＰ−メトキシケイ皮酸エステルを配
合する必要がなくなる。The compounding amount is 0.001 to 5% by weight, preferably 0.01 to 1% by weight, and more preferably 0.05 to 0% by weight based on the total amount of the external preparation for skin.
It is 1% by weight. If it is less than 0.001% by weight, the effect of glycyrrhizic acid and / or its derivative cannot be expected,
When it exceeds 5% by weight, it is not necessary to add P-methoxycinnamic acid ester.
本発明で用いられるＰ−メトキシケイ皮酸エステルは、
特許第1262218号に記載されるもので、特許請求の範囲
で示した一般式（１）〜（５）の化合物であり、これら
を一種または二種以上組合せて使用される。The P-methoxycinnamic acid ester used in the present invention is
The compounds described in Japanese Patent No. 1262218 are the compounds of the general formulas (1) to (5) shown in the claims, and they are used alone or in combination of two or more.
皮膚外用剤への配合量は、グリチルリチン酸および／ま
たは、その誘導体の１種または２種以上に対して重量で
1/100倍量以上に、好ましくは、1/10倍量以上、さらに
好ましくは、１倍量以上である。The amount of the compound to be applied to the external preparation for skin is by weight with respect to one or more glycyrrhizic acid and / or its derivatives.
The amount is 1/100 times or more, preferably 1/10 times or more, more preferably 1 times or more.
1/100倍量未満では、グリチルリチン酸および／また
は、その誘導体の効果を増加させる作用が少なく充分で
はない。グリチルリチン酸および／または、その誘導体
の１種または２種以上とＰ−メトキシケイ皮酸エステル
を配合できる皮膚外用剤は、通常考えられる皮膚外用剤
基剤、たとえば、可溶化系、乳化系、粉末系、粉末分散
系、水／油系２層状化粧料、水／油／粉末系３層状化粧
料などどのような基剤でもよい。If the amount is less than 1/100 times, the effect of increasing the effect of glycyrrhizic acid and / or its derivative is small and insufficient. Glycyrrhizic acid and / or one or more of derivatives thereof and a P-methoxycinnamic acid ester can be blended with the skin external preparation as a generally considered skin external preparation base, for example, a solubilizing system, an emulsifying system, a powder. Any base such as a system, a powder dispersion system, a water / oil / two-layer cosmetic composition, a water / oil / powder three-layer cosmetic composition may be used.
本発明の皮膚外用剤には、本発明の効果を損なわない量
的、質的範囲内で、必要に応じて動植物油やエステル
油、トリグリセライドあるいは、高級脂肪酸、高級アル
コールなどの天然抽出物、多価アルコール、そのほかの
糖誘導体、ピロリドンカルボン酸などの保湿剤、水溶性
高分子化合物や粘土鉱物などの増粘剤、防腐剤、界面活
性剤、金属イオン封鎖剤、紫外線吸収剤、無機あるい
は、有機の粉末、顔料、薬効成分、色素、香料等を配合
できる。The external preparation for skin of the present invention contains, in a quantitative and qualitative range that does not impair the effects of the present invention, natural extracts such as animal and vegetable oils, ester oils, triglycerides, higher fatty acids, and higher alcohols, if necessary. Polyhydric alcohols, other sugar derivatives, moisturizers such as pyrrolidonecarboxylic acid, thickeners such as water-soluble polymer compounds and clay minerals, preservatives, surfactants, sequestering agents, ultraviolet absorbers, inorganic or organic Powders, pigments, medicinal ingredients, dyes, fragrances, etc. can be added.
［発明の効果］ 本発明の皮膚外用剤は、つぎのような利点をもってい
る。[Effects of the Invention] The external preparation for skin of the present invention has the following advantages.
グリチルリチン酸および／または、その誘導体の持つ抗
炎症効果を副作用なく著しく増加させることができる。The anti-inflammatory effect of glycyrrhizic acid and / or its derivative can be significantly increased without side effects.
［実施例］ つぎに、試験例および実施例によって、本発明をさらに
詳細に説明する。なお、本発明は、これによって限定さ
れるものではない。EXAMPLES Next, the present invention will be described in more detail by way of test examples and examples. The present invention is not limited to this.
試験例1. 下記の処方のクリームを用い、夏の海岸でパネル50人の
日焼け後の炎症の程度を観察し評価した。Test Example 1. Using the cream having the following formulation, the degree of inflammation after sunburn of 50 panels was observed and evaluated on a summer beach.
A. セタノール 0.5 ％ ワセリン 2.0 スクワラン 7.0 自己乳化型モノステアリン酸グリセリン 2.5 ポリオキシエチレンソルビタンモノステアリン酸エステ
ル（20モル） 1.5 ジーパラメトキシケイ皮酸−モノ−２−エチルヘキサン
酸グリセリル ０〜15.0 グリチルリチン酸 ０〜5.0 B. グリセリン 10.0 ビーガム（モンモリロナイト） 5.0 水酸化カリウム 0.3 エデト酸三ナトリウム塩 0.02 水 残余 −製法− Ａ（油相）とＢ（水相）をそれぞれ70℃に加熱し、完全
溶解する。ＡをＢに加えて、乳化機で乳化する。乳化物
を熱交換機を用いて冷却してクリームを得た。A. Cetanol 0.5% Vaseline 2.0 Squalane 7.0 Self-emulsifying glycerin monostearate 2.5 Polyoxyethylene sorbitan monostearate (20 mol) 1.5 Diparamethoxycinnamic acid-glyceryl mono-2-ethylhexanoate 0-15.0 Glycyrrhizic acid 0 ~ 5.0 B. Glycerin 10.0 Veegum (montmorillonite) 5.0 Potassium hydroxide 0.3 Edetate trisodium salt 0.02 Water Residue-Process-A (oil phase) and B (water phase) are heated to 70 ° C to completely dissolve. Add A to B and emulsify with an emulsifier. The emulsion was cooled using a heat exchanger to obtain a cream.
結果を表−１に示す。The results are shown in Table-1.
１日後の炎症の程度の評価は、次の表示で表する。The evaluation of the degree of inflammation after 1 day is represented by the following display.
◎ 50名中０〜９名が炎症を惹起した。◎ 0 to 50 out of 50 people caused inflammation.
○ 50名中10〜19名が炎症を惹起した。○ 10 to 19 of the 50 people caused inflammation.
△ 50名中20〜29名が炎症を惹起した。Δ 20 to 29 out of 50 people caused inflammation.
× 50名中30名以上が炎症を惹起した。× More than 30 out of 50 people caused inflammation.
実施例１ クリーム A.ステアリン酸 10.0％ ステアリルアルコール 4.0 ステアリン酸ブチル 8.0 ステアリン酸モノグリセリンエステル 2.0 ジーパラメトキシケイ皮酸−モノ−２−エチルヘキサ
ン酸グリセリル 2.0 グリチルリチン酸ステアレート 0.8 香料 0.4 防腐剤 適量 B.プロピレングリコール 10.0 グリセリン 4.0 マルチトール 1.0 水酸化カリウム 0.4 精製水 残余 Ａの油相部とＢの水相部をそれぞれ70℃に加熱し完全溶
解する。Ａ相をＢ相に加えて、乳化機で乳化する。乳化
物を熱交換機を用いて冷却してクリームを得た。 Example 1 Cream A. Stearic acid 10.0% Stearyl alcohol 4.0 Butyl stearate 8.0 Stearate monoglycerin ester 2.0 Diparamethoxycinnamic acid-glyceryl mono-2-ethylhexanoate 2.0 Glycyrrhizinate stearate 0.8 Perfume 0.4 Preservative Amount B. Propylene glycol 10.0 Glycerin 4.0 Maltitol 1.0 Potassium hydroxide 0.4 Purified water Residue Heat the oil phase part of A and the water phase part of B to 70 ° C to completely dissolve them. Phase A is added to phase B and emulsified with an emulsifier. The emulsion was cooled using a heat exchanger to obtain a cream.
実施例２ クリーム A.セタノール 4.0 ％ ワセリン 7.0 イソプロピルミリステート 8.0 スクワラン 15.0 ステアリン酸モノグリセリンエステル 2.2 POE（20）ソルビタンモノステアレート 2.8 ジーパラメトキシケイ皮酸−モノ−２−エチルヘキサ
ン酸グリセリル 0.05 グリチルリチン酸ジカリウム 2.0 グリチルリチン酸 3.0 香料 0.3 防腐剤 適量 B.グリセリン 10.0 ジプロピレングリコール 5.0 エデト酸三ナトリウム塩 0.01 精製水 残余 実施例１に準じてナイトクリームを得た。Example 2 Cream A. Cetanol 4.0% Vaseline 7.0 Isopropyl myristate 8.0 Squalane 15.0 Stearic acid monoglycerin ester 2.2 POE (20) sorbitan monostearate 2.8 Diparamethoxycinnamic acid-glyceryl mono-2-ethylhexanoate 0.05 Dipotassium glycyrrhizinate 2.0 Glycyrrhizic acid 3.0 Fragrance 0.3 Preservative Suitable amount B. Glycerin 10.0 Dipropylene glycol 5.0 Edetate trisodium salt 0.01 Purified water Residue A night cream was obtained according to Example 1.
実施例３ 乳液 A.スクワラン 5.0 ％ オレイルオレート 3.0 ワセリン 2.0 ソルビタンセスキオレイン酸エステル 0.8 ポリオキシエチレンオレイルエーテル（20モル） 1.2 ジーパラメトキシケイ皮酸−モノ−２−エチルヘキサ
ン酸グリセリル 1.425 モノ−パラメトキシケイ皮酸−モノ−２−エチルヘキ
サン酸グリセリル 0.075 グリチルリチン酸モノアンモニウム 0.5 香料 0.3 防腐剤 適量 B.1.3ブチレングリコール 5.0 エタノール 3.0 カルボキシビニルポルリマー 0.2 水酸化カリムウ 0.1 精製水 残余 実施例１に準じて乳液を得た。Example 3 Emulsion A. Squalane 5.0% oleyl oleate 3.0 Vaseline 2.0 sorbitan sesquioleate 0.8 polyoxyethylene oleyl ether (20 mol) 1.2 diparamethoxycinnamic acid-glyceryl mono-2-ethylhexanoate 1.425 mono-paramethoxysilicic acid Cinnamic acid-glyceryl mono-2-ethylhexanoate 0.075 Monoammonium glycyrrhizinate 0.5 Perfume 0.3 Preservative A suitable amount B.1.3 Butylene glycol 5.0 Ethanol 3.0 Carboxyvinylpollimer 0.2 Kalimu hydroxide 0.1 Purified water Residue A milky lotion was prepared according to Example 1. Obtained.
実施例４ ファウンデーション A.セタノール 3.5％ 脱臭ラノリン 4.0 ホホバ油 5.0 ワセリン 2.0 スクワラン 6.0 ステアリン酸モノグリセリンエステル 2.5 POE（60）硬化ヒマシ油 1.5 POE（20）セチルエーテル 1.0 ジーパラメトキシケイ皮酸−モノ−２−エチルヘキサ
ン酸グリセリル 9.5 モノ−パラメトキシケイ皮酸−モノ−２−エチルヘキ
サン酸グリセリル 0.5 グリチルレチン酸 0.5 防腐剤 適量 香料 0.3 B.プロピレングリコール 10.0 調合粉末 12.0 エデト酸三ナトリウム塩 0.5 精製水 残余 実施例１に準じてファウンデーションを得た。Example 4 Foundation A. Cetanol 3.5% deodorized lanolin 4.0 jojoba oil 5.0 vaseline 2.0 squalane 6.0 stearic acid monoglycerin ester 2.5 POE (60) hydrogenated castor oil 1.5 POE (20) cetyl ether 1.0 diparamethoxycinnamic acid-mono-2- Glyceryl ethylhexanoate 9.5 Mono-paramethoxycinnamic acid-glyceryl mono-2-ethylhexanoate 0.5 Glycyrrhetinic acid 0.5 Preservative A suitable amount Fragrance 0.3 B. Propylene glycol 10.0 Formulated powder 12.0 Edetate trisodium salt 0.5 Purified water Residual Example 1 The foundation was obtained according to.
実施例５ 柔軟化粧水 A.エタノール 5.0 ％ POEオレイルアルコールエーテル 2.0 ２−エチルヘキシル−Ｐ−ジメチルアミノベンゾエー
ト 0.18 ジ−パラメトキシケイ皮酸−モノ−２−エチルヘキサ
ン酸グリセリル 0.07 グリチルリチン酸 0.05 香料 0.05 B.1.3ブチレングリコール 10.0 グリセリン 5.0 エデト酸三ナトリウム塩 0.01 精製水 残余 Ａのアルコール相をＢの水相に添加し、可溶化して化粧
水を得た。Example 5 Soft lotion A. Ethanol 5.0% POE oleyl alcohol ether 2.0 2-Ethylhexyl-P-dimethylaminobenzoate 0.18 Di-paramethoxycinnamic acid-glyceryl mono-2-ethylhexanoate 0.07 Glycyrrhizic acid 0.05 Perfume 0.05 B. 1.3 Butylene glycol 10.0 Glycerin 5.0 Edetate trisodium salt 0.01 Purified water Residual A alcohol phase was added to B aqueous phase and solubilized to obtain lotion.
Claims (1)
−メトキシケイ皮酸エステル化合物の一種または二種以
上0.1〜15重量％と、グリチルリチン酸およびその誘導
体の一種または二種以上0.001〜５重量％とを含有し、
両者の合計が1.1％以上であることを特徴とする皮膚外
用剤。 （式中のR1は炭素数５〜17の飽和側鎖状脂肪酸に由来す
るアルキル基を示し、R2は炭素数１〜２のアルキル基を
示し、R3はオルト又はパラ位の−OCH3基を示す。）1. P represented by the following general formulas (1) to (5):
-Containing 0.1 to 15% by weight of one or more methoxycinnamate compounds and 0.001 to 5% by weight of one or more of glycyrrhizic acid and its derivatives,
A skin external preparation characterized in that the total of both is 1.1% or more. (In the formula, R 1 represents an alkyl group derived from a saturated side chain fatty acid having 5 to 17 carbon atoms, R 2 represents an alkyl group having 1 to 2 carbon atoms, and R 3 represents an ortho or para -OCH group. Shows 3 units.)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61111328A JPH0729911B2 (en) | 1986-05-15 | 1986-05-15 | External skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61111328A JPH0729911B2 (en) | 1986-05-15 | 1986-05-15 | External skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62267215A JPS62267215A (en) | 1987-11-19 |
| JPH0729911B2 true JPH0729911B2 (en) | 1995-04-05 |
Family
ID=14558420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61111328A Expired - Fee Related JPH0729911B2 (en) | 1986-05-15 | 1986-05-15 | External skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0729911B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000136122A (en) * | 1998-10-28 | 2000-05-16 | Kose Corp | Skin lotion |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2916351B1 (en) | 2007-05-22 | 2012-12-07 | Galderma Res & Dev | PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS SELECTED BY PYRROLIDONE-5-CARBOXYLIC ACID, CITRULLINE, ARGININE AND ASPARAGINE AND THEIR USE IN THE TREATMENT OF ATOPIC DERMATITIS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5935941B2 (en) * | 1979-04-02 | 1984-08-31 | 株式会社資生堂 | UV absorber |
| JPS59196813A (en) * | 1983-04-25 | 1984-11-08 | Kao Corp | Melanin inhibitor |
-
1986
- 1986-05-15 JP JP61111328A patent/JPH0729911B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000136122A (en) * | 1998-10-28 | 2000-05-16 | Kose Corp | Skin lotion |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62267215A (en) | 1987-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3888470B2 (en) | Skin protective composition containing emulsified petrolatum | |
| JP3609834B2 (en) | Skin preparation | |
| KR100638417B1 (en) | Hydrogenated castor oil dispersed in lipid for pharmaceutically suitable topical ointment | |
| JP3509108B2 (en) | Water-in-oil emulsifier composition | |
| AU687502B2 (en) | Dermatologic composition | |
| JP3344822B2 (en) | External preparation for skin | |
| JP4070065B2 (en) | Skin preparation for preventing and improving skin roughness | |
| US20040191206A1 (en) | Methods for reduction of inflammation and erythema | |
| JPH03178916A (en) | Skin external agent | |
| WO1997035597A1 (en) | Acne treatment | |
| JPH064529B2 (en) | External skin preparation | |
| JP2720246B2 (en) | External preparation for skin | |
| JP2002087926A5 (en) | ||
| JPS62126128A (en) | External preparation composition | |
| JPH0729911B2 (en) | External skin preparation | |
| JPH0623089B2 (en) | External skin preparation | |
| JPH0625053B2 (en) | External skin preparation | |
| JPH0995411A (en) | Preparation for external use for skin | |
| JP2003277250A (en) | Skin care preparation | |
| JPH07215839A (en) | Skin external agent | |
| JP2000256168A (en) | Skin lotion | |
| JPH11255661A (en) | Preparation for external use for atopic dermatitis | |
| JPH115725A (en) | Preparation for external use for skin | |
| JPS61215307A (en) | External agent for skin | |
| JP2003183148A (en) | Skin external preparation composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |